Skip to main content
Fig. 4 | European Journal of Medical Research

Fig. 4

From: Identification of ACBD3 as a new molecular biomarker in pan-cancers through bioinformatic analysis: a preclinical study

Fig. 4

ACBD3 expression in different molecular subtypes of various TCGA cancers. brain lower grade glioma (LGG), breast invasive carcinoma (BRCA), prostate adenocarcinoma (PRAD), pheochromocytoma and paraganglioma (PCPG), colon adenocarcinoma (COAD), ovarian serous cystadenocarcinoma (OV), lung squamous cell carcinoma (LUSC), liver hepatocellular carcinoma (LIHC), stomach adenocarcinoma (STAD), skin cutaneous melanoma (SKCM), kidney renal papillary cell carcinoma (KIRP), head and neck squamous cell carcinoma (HNSC). ACBD3 expressed the highest in the molecular subtype of A G-CIMP-high in LGG, B LunA in BRCA, C 1-ERG in PRAD, D Kinasesignaling in PCPG, E CIN in COAD, F Immunoreactive and Proliferative in OV, G classical in LUSC, H iCluster:1 in LIHC, I CIN in STAD, J BRAF_Hotspot_Mutants in SKCM, K C1in KIRP, and L Basal in HNSC

Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us